Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase
- PMID: 20570525
- DOI: 10.1016/j.bmc.2010.05.032
Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase
Abstract
We report here the discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase by adopting a strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and bioassay. Thirty two compounds were selected and synthesized. All compounds showed potent inhibitory activity against c-Src kinase with IC₅₀ values ranging from 3.14 μM to 0.02 μM. Compound 5i was identified as one of the most potent agent with an IC₅₀ 120 times lower than those of the hits. The high hit rate (100%) and the potency of the new Src kinase inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening. The novel active chemical entities reported here should be good leads for further development of purine-based anticancer drugs targeting Src tyrosine kinase.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22. Breast Cancer Res Treat. 2011. PMID: 21181437
-
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.Chem Biol Drug Des. 2006 Jan;67(1):46-57. doi: 10.1111/j.1747-0285.2005.00316.x. Chem Biol Drug Des. 2006. PMID: 16492148
-
Structure-based virtual screening of Src kinase inhibitors.Bioorg Med Chem. 2009 Apr 15;17(8):3152-61. doi: 10.1016/j.bmc.2009.02.054. Epub 2009 Mar 5. Bioorg Med Chem. 2009. PMID: 19321350
-
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.Curr Opin Drug Discov Devel. 2003 Sep;6(5):729-41. Curr Opin Drug Discov Devel. 2003. PMID: 14579523 Review.
-
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review.
Cited by
-
Computational methods for drug design and discovery: focus on China.Trends Pharmacol Sci. 2013 Oct;34(10):549-59. doi: 10.1016/j.tips.2013.08.004. Epub 2013 Sep 11. Trends Pharmacol Sci. 2013. PMID: 24035675 Free PMC article. Review.
-
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.Eur J Med Chem. 2021 Nov 15;224:113683. doi: 10.1016/j.ejmech.2021.113683. Epub 2021 Jul 5. Eur J Med Chem. 2021. PMID: 34273661 Free PMC article.
-
Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.ACS Med Chem Lett. 2019 Jan 23;10(4):558-563. doi: 10.1021/acsmedchemlett.8b00583. eCollection 2019 Apr 11. ACS Med Chem Lett. 2019. PMID: 30996796 Free PMC article.
-
Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery.Sci Rep. 2016 Feb 22;6:21509. doi: 10.1038/srep21509. Sci Rep. 2016. PMID: 26898318 Free PMC article.
-
Newly synthesized 6-substituted piperazine/phenyl-9-cyclopentyl containing purine nucleobase analogs act as potent anticancer agents and induce apoptosis via inhibiting Src in hepatocellular carcinoma cells.RSC Med Chem. 2023 Nov 10;14(12):2658-2676. doi: 10.1039/d3md00440f. eCollection 2023 Dec 13. RSC Med Chem. 2023. PMID: 38107180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous